Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ORITAVANCIN DIPHOSPHATE vs OSPEMIFENE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ORITAVANCIN DIPHOSPHATE vs OSPEMIFENE: Safety Overview

Metric ORITAVANCIN DIPHOSPHATE OSPEMIFENE
Total FAERS Reports 276 2,047
Deaths Reported 4 2
Death Rate 1.4% 0.1%
Hospitalizations 27 60
Average Patient Age 58.5 yrs 61.7 yrs
% Female Patients 39.2% 99.8%
FDA Approval Date Aug 6, 2014 Feb 13, 2024
Manufacturer Melinta Therapeutics, LLC Duchesnay USA, Inc.
Route INTRAVENOUS ORAL
Marketing Status Prescription Prescription